Cerebrovascular reserve

Candesartan preserved cerebrovascular reserve over 12 months (no significant within-group decline in vasoreactivity or VMR), whereas lisinopril and HCTZ groups showed significant declines. However, be

Effect: null; Between-group p=0.30 for vasoreactivity; p=0.46 for VMR

Candesartan preserved cerebrovascular reserve over 12 months (no significant within-group decline in vasoreactivity or VMR), whereas lisinopril and HCTZ groups showed significant declines. However, be

Effect: null; Between-group p=0.30 for vasoreactivity; p=0.46 for VMR

Candesartan preserved cerebrovascular reserve over 12 months (no significant within-group decline in vasoreactivity or VMR), whereas lisinopril and HCTZ groups showed significant declines. However, be

Effect: null; Between-group p=0.30 for vasoreactivity; p=0.46 for VMR

Candesartan preserved cerebrovascular reserve over 12 months (no significant within-group decline in vasoreactivity or VMR), whereas lisinopril and HCTZ groups showed significant declines. However, be

Effect: null; Between-group p=0.30 for vasoreactivity; p=0.46 for VMR

Candesartan preserved cerebrovascular reserve over 12 months (no significant within-group decline in vasoreactivity or VMR), whereas lisinopril and HCTZ groups showed significant declines. However, be

Effect: null; Between-group p=0.30 for vasoreactivity; p=0.46 for VMR

Candesartan preserved cerebrovascular reserve over 12 months (no significant within-group decline in vasoreactivity or VMR), whereas lisinopril and HCTZ groups showed significant declines. However, be

Effect: null; Between-group p=0.30 for vasoreactivity; p=0.46 for VMR

Candesartan preserved cerebrovascular reserve over 12 months (no significant within-group decline in vasoreactivity or VMR), whereas lisinopril and HCTZ groups showed significant declines. However, be

Effect: null; Between-group p=0.30 for vasoreactivity; p=0.46 for VMR

Candesartan preserved cerebrovascular reserve over 12 months (no significant within-group decline in vasoreactivity or VMR), whereas lisinopril and HCTZ groups showed significant declines. However, be

Effect: null; Between-group p=0.30 for vasoreactivity; p=0.46 for VMR

Candesartan preserved cerebrovascular reserve over 12 months (no significant within-group decline in vasoreactivity or VMR), whereas lisinopril and HCTZ groups showed significant declines. However, be

Effect: null; Between-group p=0.30 for vasoreactivity; p=0.46 for VMR

Candesartan preserved cerebrovascular reserve over 12 months (no significant within-group decline in vasoreactivity or VMR), whereas lisinopril and HCTZ groups showed significant declines. However, be

Effect: null; Between-group p=0.30 for vasoreactivity; p=0.46 for VMR

Candesartan preserved cerebrovascular reserve over 12 months (no significant within-group decline in vasoreactivity or VMR), whereas lisinopril and HCTZ groups showed significant declines. However, be

Effect: null; Between-group p=0.30 for vasoreactivity; p=0.46 for VMR

Candesartan preserved cerebrovascular reserve over 12 months (no significant within-group decline in vasoreactivity or VMR), whereas lisinopril and HCTZ groups showed significant declines. However, be

Effect: null; Between-group p=0.30 for vasoreactivity; p=0.46 for VMR

Candesartan preserved cerebrovascular reserve over 12 months (no significant within-group decline in vasoreactivity or VMR), whereas lisinopril and HCTZ groups showed significant declines. However, be

Effect: null; Between-group p=0.30 for vasoreactivity; p=0.46 for VMR

Candesartan preserved cerebrovascular reserve over 12 months (no significant within-group decline in vasoreactivity or VMR), whereas lisinopril and HCTZ groups showed significant declines. However, be

Effect: null; Between-group p=0.30 for vasoreactivity; p=0.46 for VMR

Candesartan preserved cerebrovascular reserve over 12 months (no significant within-group decline in vasoreactivity or VMR), whereas lisinopril and HCTZ groups showed significant declines. However, be

Effect: null; Between-group p=0.30 for vasoreactivity; p=0.46 for VMR

Candesartan preserved cerebrovascular reserve over 12 months (no significant within-group decline in vasoreactivity or VMR), whereas lisinopril and HCTZ groups showed significant declines. However, be

Effect: null; Between-group p=0.30 for vasoreactivity; p=0.46 for VMR

Candesartan preserved cerebrovascular reserve over 12 months (no significant within-group decline in vasoreactivity or VMR), whereas lisinopril and HCTZ groups showed significant declines. However, be

Effect: null; Between-group p=0.30 for vasoreactivity; p=0.46 for VMR

Candesartan preserved cerebrovascular reserve over 12 months (no significant within-group decline in vasoreactivity or VMR), whereas lisinopril and HCTZ groups showed significant declines. However, be

Effect: null; Between-group p=0.30 for vasoreactivity; p=0.46 for VMR

Candesartan preserved cerebrovascular reserve over 12 months (no significant within-group decline in vasoreactivity or VMR), whereas lisinopril and HCTZ groups showed significant declines. However, be

Effect: null; Between-group p=0.30 for vasoreactivity; p=0.46 for VMR

Candesartan preserved cerebrovascular reserve over 12 months (no significant within-group decline in vasoreactivity or VMR), whereas lisinopril and HCTZ groups showed significant declines. However, be

Effect: null; Between-group p=0.30 for vasoreactivity; p=0.46 for VMR

Candesartan preserved cerebrovascular reserve over 12 months (no significant within-group decline in vasoreactivity or VMR), whereas lisinopril and HCTZ groups showed significant declines. However, be

Effect: null; Between-group p=0.30 for vasoreactivity; p=0.46 for VMR

Candesartan preserved cerebrovascular reserve over 12 months (no significant within-group decline in vasoreactivity or VMR), whereas lisinopril and HCTZ groups showed significant declines. However, be

Effect: null; Between-group p=0.30 for vasoreactivity; p=0.46 for VMR

Candesartan preserved cerebrovascular reserve over 12 months (no significant within-group decline in vasoreactivity or VMR), whereas lisinopril and HCTZ groups showed significant declines. However, be

Effect: null; Between-group p=0.30 for vasoreactivity; p=0.46 for VMR

Candesartan preserved cerebrovascular reserve over 12 months (no significant within-group decline in vasoreactivity or VMR), whereas lisinopril and HCTZ groups showed significant declines. However, be

Effect: null; Between-group p=0.30 for vasoreactivity; p=0.46 for VMR

Candesartan preserved cerebrovascular reserve over 12 months (no significant within-group decline in vasoreactivity or VMR), whereas lisinopril and HCTZ groups showed significant declines. However, be

Effect: null; Between-group p=0.30 for vasoreactivity; p=0.46 for VMR

Candesartan preserved cerebrovascular reserve over 12 months (no significant within-group decline in vasoreactivity or VMR), whereas lisinopril and HCTZ groups showed significant declines. However, be

Effect: null; Between-group p=0.30 for vasoreactivity; p=0.46 for VMR

Candesartan preserved cerebrovascular reserve over 12 months (no significant within-group decline in vasoreactivity or VMR), whereas lisinopril and HCTZ groups showed significant declines. However, be

Effect: null; Between-group p=0.30 for vasoreactivity; p=0.46 for VMR